Brief: Lantern Pharma Receives Ind Clearance From FDA Enabling Phase 1 Initiation For Drug Candidate Lp-284 In Non-Hodgkin’S Lymphomas
18/09/2023 14:12
Sept 18 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA RECEIVES IND CLEARANCE FROM FDA ENABLING
PHASE 1
INITIATION FOR DRUG CANDIDATE LP-284 IN NON-HODGKIN’S LYMPHOMAS
* EXPECTS TO COMMENCE ENROLLMENT OF PATIENTS FOR
FIRST-IN-HUMAN
PHASE 1 TRIAL FOR LP-284 DURING Q4
Source text for Eikon: ID:nBw8SqSJNa
Further company coverage: LTRN.O
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments